DalsnaFinance

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Markets PR Newswire By PR Newswire 25 Jun 2026 12:30 1 min read
Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

This clinical trial further enhances Servier's neurology franchise focused on targeting rare indications for patients with significant unmet needs Global clinical trial sites are open and enrolling in the U.S., Europe and Japan BOSTON, June 25, 2026 /PRNewswire/ -- Servier today announced...

This clinical trial further enhances Servier's neurology franchise focused on targeting rare indications for patients with significant unmet needs Global clinical trial sites are open and enrolling in the U.S., Europe and Japan BOSTON, June 25, 2026 /PRNewswire/ -- Servier today announced...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.